Goldman Sachs
IOVA icon

Goldman Sachs’s Iovance Biotherapeutics IOVA Stock Holding History

Goldman Sachs’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,000
Closed -$416K – 6574
2022
Q1 		$416K Buy
25,000
+2,800
+13% +$43.3K ﹤0.01% 5452
2021
Q4 		$424K Buy
+22,200
New +$489K ﹤0.01% 5478
2021
Q3 		– Sell
-40,000
Closed -$1.04M – 6355
2021
Q2 		$1.04M Buy
+40,000
New +$1.04M ﹤0.01% 4727
2020
Q2 		– Sell
-60,000
Closed -$1.8M – 5343
2020
Q1 		$1.8M Buy
+60,000
New +$1.59M ﹤0.01% 3377
2018
Q1 		– Sell
-2,600
Closed -$21K – 6134
2017
Q4 		$21K Sell
2,600
-2,500
-49% -$20.1K ﹤0.01% 6108
2017
Q3 		$40K Buy
+5,100
New +$32.3K ﹤0.01% 6304
2017
Q2 		– Sell
-1,900
Closed -$14K – 6851
2017
Q1 		$14K Sell
1,900
-600
-24% -$4.4K ﹤0.01% 6572
2016
Q4 		$17K Buy
2,500
+1,100
+79% +$7.57K ﹤0.01% 6677
2016
Q3 		$12K Sell
1,400
-101,100
-99% -$855K ﹤0.01% 6850
2016
Q2 		$830K Buy
102,500
+100,600
+5,295% +$632K ﹤0.01% 4363
2016
Q1 		$10K Buy
+1,900
New +$10.4K ﹤0.01% 6895

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's IOVA Position: Q1 2026 in Review

Goldman Sachs increased its Iovance Biotherapeutics (IOVA) stake by 1.8% in Q1 2026, buying an estimated $488K and bringing the position to 8,760,060 shares worth $30.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2034.

Goldman Sachs first reported a position in IOVA in Q1 2015 and has held it in 44 quarters since. The position peaked at $60.7M in Q1 2021. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Goldman Sachs held 8,760,060 shares of Iovance Biotherapeutics worth $30.7M as of Q1 2026.
  • Goldman Sachs bought 152,496 Iovance Biotherapeutics shares in Q1 2026, an estimated $488K.
  • Iovance Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2034 holding.
  • Goldman Sachs first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 44 quarters since.
  • Goldman Sachs's Iovance Biotherapeutics position peaked at $60.7M in Q1 2021.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.